Moreover, 71,42% (15/21) of PDO obtained from TB samples belonged to primary lesions of HER2-negative tumors, while 23,81% (7/21) were from HER2-positive and 4,76% (1/21) Triple Negative Breast cancer (TNBC). Here, ERBB2 is linked to breast cancer.